September 1, 1994Pacing and Clinical Electrophysiology
Clinical Surveillance of an Active Fixation, Bipolar, Polyurethane Insulated Pacing Lead, Part II: The Ventricular Lead
Key result
Surveillance of 72 Telectronics 330-201 ventricular leads showed 5.6% acute and 8.3% chronic lead-related complications, with 14.3% of examined patients developing high pacing thresholds.
Why the study?
What is the incidence of acute and chronic complications associated with the Telectronics 330-201 active fixation ventricular lead?
Population
72 patients implanted with Telectronics 330-201 active fixation, polyurethane insulated ventricular leads at…
Design
Case_series
Follow-up
up to 2.7 years (median 9.4 months)
Authors
Discussion
Loading...
Member takes
Implication
Supports heightened vigilance for Telectronics 330-201 lead complications; leaves open need for prospective validation in larger cohorts.
Study Design
Type
Observational (n=72)
Multicenter
No
Structured PICO
What is the incidence of acute and chronic complications associated with the Telectronics 330-201 active fixation ventricular lead?
P
Population
72 patients implanted with Telectronics 330-201 active fixation ventricular leads at the Mayo Clinic, followed for a median of 9.4 months.
E
Exposure
Telectronics 330-201 active fixation, polyurethane insulated ventricular lead (Accufix)
O
Outcome
Acute and chronic lead related complicationssafety
The Telectronics 330-201 ventricular lead showed a 5.6% acute and 8.3% chronic complication rate, with 14.3% of patients developing high pacing thresholds.
Cite This Study
Glikson et al. (1994) conducted an observational in Patients requiring ventricular pacing leads (n=72). Telectronics 330-201 active fixation, polyurethane insulated ventricular leads (Accufix) was evaluated on Lead related complications (acute and chronic). Surveillance of 72 Telectronics 330-201 ventricular leads showed 5.6% acute and 8.3% chronic lead-related complications, with 14.3% of examined patients developing high pacing thresholds.